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Relevance statement (100 words) 
International guidelines recommend that people taking antipsychotics should be offered 
lifestyle interventions to address weight gain. Many mental health services struggle to 
implement this, because of insufficient evidence to inform commissioning. Using robust 
methodology, we developed STEPWISE, a theoretically informed, group-based structured 
education intervention to support weight loss in people with schizophrenia. We conducted 
the largest randomised controlled study of a lifestyle intervention for people with 
schizophrenia. STEPWISE was not effective in reducing weight. Before lifestyle interventions 
are commissioned across the NHS, it is vital that further research is undertaken to address 
how to support weight management in this population. 
  
Abstract 
Background: Obesity is a major challenge for people with schizophrenia.  
Aim: We assessed whether STEPWISE, a theory-based, group structured lifestyle education 
programme could support weight reduction in people with schizophrenia. 
Methods: In this randomised controlled trial, we recruited adults with schizophrenia, 
schizoaffective disorder or first episode psychosis from ten mental health organisations in 
England. Participants were randomly allocated to the STEPWISE intervention or treatment as 
usual. The 12-month intervention comprised four 2.5 hour weekly group sessions, followed 
by two-weekly maintenance contact and group sessions at 4, 7 and 10 months. The primary 
outcome was weight change after 12 months. Key secondary outcomes included diet, physical 
activity, biomedical measures and patient related outcome measures. Cost-effectiveness was 
assessed and a mixed-methods process evaluation was included. 
Results: Between 10 March 2015 and 31 March 2016, we recruited 414 people (intervention 
208, usual care 206) with 341 (84.4%) participants completing the trial. At 12 months, weight 
reduction did not differ between groups (mean difference 0.0 Kg, 95% CI -1.6 to 1.7, p=0.963); 
physical activity, dietary intake and biochemical measures were unchanged. STEPWISE was 
well-received by participants and facilitators. The healthcare perspective incremental cost-
effectiveness ratio was £246,921 per quality-adjusted life-year gained. 
Conclusions: Participants were successfully recruited and retained, indicating a strong 
interest in weight interventions; however, the STEPWISE intervention was neither clinically 
nor cost-effective. Further research is needed to determine how to manage overweight and 
obesity in people with schizophrenia. 
Declaration of Interest: None relevant to the trial; full disclosure is available in the paper. 
Study registration: ISRCTN19447796. 
Funding details: National Institute for Health Research (NIHR) Heath Technology Assessment 
(HTA) programme (HTA 12/28/05) 
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Introduction 
People with schizophrenia die 10-20 years earlier than the general population, with 
approximately 75% of deaths resulting from physical illness (1). The two-fold increased 
prevalence of overweight and obesity contributes to this excess mortality (2). Some, but not 
all, studies suggest that dietary and physical activity interventions may reduce weight gain (3-
7).  
Many weight loss programmes involve one-to-one strategies to promote behaviour change 
but these are unlikely to be affordable in many healthcare settings (8). Group-based 
structured education offers an alternative approach (9), and has been adopted by the UK NHS 
Diabetes Prevention Programme (10). The National Institute for Health and Care Excellence 
(NICE) recommends that lifestyle interventions should be offered to people taking 
antipsychotics but there is insufficient evidence to inform how this should be commissioned 
(11). 
We designed the STEPWISE group-based lifestyle structured education and then conducted a 
randomised controlled trial (RCT) to evaluate whether STEPWISE could lead to clinically 
relevant weight loss after a year in adults with schizophrenia, schizoaffective disorder or first 
episode psychosis. Further objectives were to assess the impact on physical activity, diet, 
biomedical measures and quality of life, intervention fidelity, acceptability to participants and 
mental health services, and cost-effectiveness. 
Methods 
Study Design 
STEPWISE was a two-arm, parallel group RCT comparing the STEPWISE intervention with 
treatment as usual (TAU). The study took place in ten English NHS Mental Health Trusts in 
urban and rural locations. The trial was approved by UK National Research Ethics Committee, 
Yorkshire & the Humber - South Yorkshire, (reference 14/YH/0019) and conducted in 
accordance with Good Clinical Practice. The trial protocol has been reported (12).  
Participants 
Researchers at each site worked with local mental health clinicians to identify potentially 
eligible patients from clinic lists and case notes. We used posters and leaflets to encourage 
self-referral. We recruited adults (≥18 years) with a clinical diagnosis of schizophrenia, 
schizoaffective disorder (ICD-10 codes F20, F25) or first episode psychosis (defined as <3 years 
since presentation to mental health services). The Operational Criteria Checklist (OPCRIT+) 
was completed using case note review to assess whether the clinical diagnosis matched an 
objective measure of psychiatric illness.  
All participants had been prescribed an antipsychotic for ≥1 month and were able and willing 
to participate in a group education programme. Participants had a body mass index (BMI) ≥25 
Kg/m2 (≥23 Kg/m2 for South Asian and Chinese backgrounds) or expressed concern about their 
weight. 
People were excluded if they had a physical illness that could seriously reduce their life 
expectancy or ability to participate, that would independently impact metabolic measures 
and weight, e.g. Cushing’s syndrome, or were currently pregnant or less than 6 months post-
partum. High levels of psychiatric symptoms, as judged by the principal investigator, which 
could seriously affect participation and ability to put into practice the learning from the 
intervention sessions were a further exclusion criterion. People with significant alcohol or 
substance misuse, primary diagnosis of psychotic depression, mania or learning disability 
were excluded. People currently (or within the past three months) engaged in a weight 
management programme or unable to speak and read English were also excluded. 
Participants provided written informed consent before trial entry. 
Randomisation and masking 
The Sheffield Clinical Trials Research Unit generated a computerised randomisation list using 
permuted blocks of random sizes to allocate participants to either TAU plus the STEPWISE 
intervention or TAU alone in a 1:1 ratio, stratified by site and time since antipsychotic 
initiation (<3 months or ≥3 months).  After randomisation, an unblinded researcher informed 
the participant and their general practitioner of the allocation. Research outcome assessors 
were blind to treatment allocation. Blind (or suspected) breaks were recorded. Due to the 
nature of the intervention, participants were not blinded.  
Interventions 
STEPWISE structured education lifestyle programme 
We developed the STEPWISE intervention using the MRC framework for complex 
interventions (appendix 1). Following a systematic literature review, a team with expertise in 
obesity, lifestyle interventions, behaviour change, mental health, and people with 
schizophrenia designed the prototype intervention, which was piloted and amended in four 
iterative cycles. 
We considered three areas that are core to weight management interventions in people with 
schizophrenia when developing the theoretical framework that guided the intervention 
(Figure 1a):  
• behaviour change theory specifically with a focus on food and physical activity;  
• psychological processes underlying weight management;  
• challenges of living with psychosis and its impact on eating and weight.  
Based on established psychological theories, appropriate behaviour change techniques were 
used to address problem behaviours. 
STEPWISE took place over approximately 12 months. Groups of participants (median 6, range 
3-11) attended a foundation course of four weekly 2.5-hour group sessions delivered by two 
trained facilitators (Figure 1b). This was followed by 1:1 support contact, mostly by telephone, 
lasting about ten minutes, approximately every two weeks for the remainder of the 
intervention period. A trained facilitator carried out the support contact to promote 
behaviour change and continued engagement. Further 2.5-hour group-based booster 
sessions took place at approximately 4, 7 and 10 months after randomisation giving a total 
intervention duration of ~25.5 hours.  
All sessions started at lunchtime with the provision of a healthy lunch. After an initial 
introduction, participants were invited to “share their story”.  This provided the facilitators 
with feedback on what changes the person had made and what remained challenging. The 
facilitators used a non-judgemental style to encourage openness, problem solving and sharing 
successful strategies. Specific changes and challenges were recorded so that the participants 
could refer back to their individualised solutions.   
The next part was entitled ‘Taking control of your weight’ to reinforce the focus of the 
intervention. Each session covered one or two aspects of how lifestyle changes could help the 
participants take control of their weight. Four topics covered diet while two focussed on 
physical activity. A facilitative approach, as opposed to a didactic teaching style, was used to 
enable participants to discuss their beliefs about weight and explore their own solutions.  
The final section was devoted to action planning, when the participants developed their own 
individualised goals and solutions. As the participants departed, they were given supporting 
tools to reinforce the key messages of the session.  
Each centre had 4-6 trained facilitators to maintain consistency across sessions and support 
contact. We recorded intervention attendance and level of support contact. We invited 
participants to complete an anonymous 6-question “session feedback” form at the end of 
each session (appendix 2a).  
Control Arm 
As no consistent lifestyle education programme was offered across sites (13), we provided 
printed advice on lifestyle and the risks associated with weight gain for all participants. We 
recorded whether participants attended other weight management or physical activity 
programmes outside the trial. 
Outcomes 
Trial assessments were undertaken at the participant’s home or Mental Health Organisation, 
after consent but before randomisation and at 3 and 12 months post randomisation 
(appendix 3).  
The primary endpoint was weight change at 12 months after randomisation. A medical and 
psychiatric history, including smoking and current medication, was obtained. Height (baseline 
only), weight, waist circumference and blood pressure were measured (appendix 2b). 
Participants wore a wrist GENEActiv accelerometer for 7 days to assess physical activity (mean 
acceleration and mean time spent in moderate-to-vigorous physical activity) (appendix 2c).  
Research staff helped participants complete the self-report questionnaires by reading the 
questions, checking understanding and providing available answer options.  We assessed 
dietary intake with the Adapted Dietary Instrument for Nutrition Education questionnaire 
(14). We used questionnaires to assess patient-reported outcome measures, including quality 
of life (RAND SF-36 and EQ-5D-5L), health beliefs (adapted Brief Illness Perception 
Questionnaire), psychiatric symptoms (Brief Psychiatric Rating Scale) and depressive 
symptoms (9-item Patient Health Questionnaire).  
Assessments of fasting glucose, glycated haemoglobin (HbA1c) and lipid profile were made at 
baseline and 12 months post-randomisation. 
Safety assessments 
We monitored adverse events at 3 and 12 months. Expected serious adverse events included 
psychiatric hospitalisation, self-harm, suicide attempt and death from suicide. An 
independent Data Monitoring Committee and Trial Steering Committee oversaw the conduct 
and safety of the trial.  
Cost-effectiveness analysis 
We undertook an economic evaluation from a health and social care and societal perspective. 
Health and Social Care costs included the costs of medicines and NHS professionals in primary 
and community care and inpatient settings, and social care costs. Societal costs were 
calculated using police costs, productivity losses from lost education and employment and 
informal care costs. The intervention cost was based on staff time plus overheads and 
included training and supervision. The Client Service Receipt Inventory was used to record 
service use. Costs were calculated using appropriate unit cost information. Cost-effectiveness 
was assessed by combining cost with the primary outcome and quality adjusted life years 
(QALY) generated from the EQ-5D-5L questionnaire. We constructed incremental cost-
effectiveness ratios (ICERs) to demonstrate the cost per extra QALY gained and uncertainty 
around estimates was explored using cost-effectiveness planes and acceptability curves.  
Process Evaluation 
We undertook a process evaluation using a published framework and a logic model that 
focused on resources, activities and process outcomes (reach, delivery, fidelity and receipt of 
intervention) (15). Qualitative data were collected via semi-structured telephone interviews 
with service users (n=24), intervention facilitators (n=20) and intervention developers (n=7). 
The interviews were recorded and coded using NVivo (QSR International v11).  
Intervention delivery fidelity was monitored by direct observation using two instruments 
(appendix 2d). The Core Facilitator Behavioural Observation Sheet assessed 35 behaviours in 
six domains.  Participant–educator interaction was assessed using the DESMOND Observation 
Tool (16). Every 10 seconds, the coder recorded whether an educator or participant was 
currently talking. Silence, laughter or multiple conversations were classed as ‘miscellaneous’. 
This provided an objective indication of facilitator versus participant talk-time.  
Sample size 
The sample size calculation was based on detecting a clinically meaningful difference of 4.5 
Kg (~5% reduction in body weight). This amount of weight loss is associated with improved 
lipid profile, glucose and blood pressure and potential reductions in cardiovascular disease 
(17). Based on previous UK data, we assumed a standard deviation (SD) of 10 Kg. 130 
participants per arm (260 in total) were required to detect this weight difference assuming 
95% power and two-sided significance level of 5%. Based on an average of seven participants 
per group, and intra-class correlation of 5% in the intervention arm, the sample size was 
inflated by a design effect of 1.3 in the intervention arm yielding revised sample sizes of 169 
and 130 in the intervention and control arms, respectively. To maintain a 1:1 allocation, 158 
participants per arm were required. We anticipated a dropout rate of 20% giving 198 
participants per arm. 
Statistical Analysis 
All analyses were by intention to treat. The primary objective was assessed by fitting a 
marginal generalised estimating equation model adjusted for baseline weight, site and years 
since antipsychotic initiation; the model incorporated an adjustment for potential clustering 
or correlation among outcomes of people treated together.  A sensitivity analysis assessed 
the robustness of the findings, in particular, to missing data mechanisms (including missing 
not at random), exploring whether the intervention had the same effect among recently 
diagnosed participants compared with those with longer illness duration.  Other continuous 
outcomes were analysed and reported as for the primary outcome. Analyses were conducted 
using the Stata 14.2 software (StataCorp. Stata Statistical Software: Release 14. TX; 2015). 
Role of the funding source 
The funder had no role in study design, data collection, data analysis, data interpretation, or 
report writing. The corresponding author had full access to all study data and had final 
responsibility for the decision to submit for publication. 
Results 
Between 10 March 2015 and 31 March 2016, we screened 1,253 patients of whom 414 
enrolled (Figure 2). The trial closed on 31 March 2017 when the last 12-month follow-up was 
completed. The commonest reasons for exclusion at screening were ineligibility and lack of 
interest. Two participants withdrew consent prior to the study commencement and were not 
included in any analyses. Therefore, 412 participants (207 intervention, 205 control) were 
included in the final intention to treat analysis. 168 (81.2%) intervention and 173 (84.4%) 
control participants completed the study. 25 (12.1%) intervention and 22 (10.7%) control 
participants withdrew consent during the study. 11 (5.3%) intervention and 10 (4.9%) control 
participants were lost to follow-up. Three deaths occurred in the intervention arm. 
At baseline, the groups were largely balanced (tables 1 and 2), but intervention participants 
were on average 3 Kg heavier at baseline, partially explained by the higher proportion of men 
in the intervention arm (55.6% vs. 46.3%). 7 control and 3 intervention participants had a BMI 
<25 Kg/m2. The OPCRIT+ concurred with the clinical diagnosis (appendix 4.1). Participants 
reported mild-to-moderate psychiatric symptoms and took a range of antipsychotics (table 
1). 24 (14.3%) intervention participants and 29 (16.7%) control participants changed 
antipsychotic during the trial. 
Intervention Uptake 
Participants commenced the STEPWISE intervention a median 15 days (range 1-101 days) 
after randomisation. Participants attended a mean of 2.7 foundation and 1.4 booster 
sessions. 111 (53.6%) participants attended ≥3 foundation sessions and ≥1 booster session, 
of whom 47 (22.7%) participants attended all foundation and booster sessions. 36 (17.4%) 
participants attended no sessions. The mean group size at randomisation was 6.3 (median 6) 
but the mean number attending ranged from 4.0 – 4.4 (median 4) during the foundation 
course and dropped to 2.7 – 3.0 (median 3) during booster sessions (appendix 4.2). 169 
(81.6%) participants had one or more support contacts, mostly by telephone (80.7% 
participants, 2,434 contacts), mail/postcard (49.3%, 555 contacts) or both (48.3%). Fewer 
participants were contacted electronically (11.6%, 88 contacts) or face-to-face (32.9%, 141 
contacts). 29 (8.6%) participants (19 intervention and 10 control) reported attending weight 
loss programmes outside the trial (appendix 4.3). 
Outcome measures 
The primary comparison of weight change at 12 months was almost identical between arms, 
with a mean reduction in weight of 0.47 Kg in intervention participants and 0.51 Kg in control 
participants (difference= 0.0 Kg, 95% CI -1.6 to 1.7, p=0.963) (Table 2, appendix figure 4.1). 
There was no difference in percentage weight loss or percentage of participants maintaining 
or losing weight.  
Weight loss was modestly associated with age, with weight reduction increasing by 0.8 Kg per 
10 additional years (95% CI 0.0 to 1.5 Kg, p=0.042). Participants with schizoaffective disorder 
had greater mean weight loss (-2.7 Kg) than those with first episode psychosis (-0.3 Kg) or 
schizophrenia (+0.01 Kg; p=0.023). There was no association between treatment effect and 
sex, baseline mental health, BMI, severity of psychiatric illness, duration and change of 
antipsychotic treatment, or attendance at an external weight loss programme. There was no 
association between total contact time and weight loss. 
The baseline self-reported diet indicated a high consumption of refined sugar from sugary 
drinks and low fibre (appendix 4.4). Although there was some evidence that alcohol intake 
fell in intervention participants, no other dietary component changed during the trial. 
Smoking status did not change (appendix 4.5). 
Both groups had similarly low physical activity levels at baseline (Table 2).  After 3-months, 
weekend moderate-to-vigorous physical activity was significantly higher in intervention 
participants, but this difference had disappeared by 12 months. No other differences were 
seen in physical activity. Self-reported patient quality of life, obesity illness perception and 
psychiatric symptoms were also similar between groups at both 3- and 12- months (Table 2; 
appendix 4.6-7). The lack of objective changes in diet and lifestyle in the intervention group 
contrasted with self-reported changes during the “Sharing Stories” part of the sessions. 
At 3 months, outcome assessors were unblinded (or suspected unblinding) at 44 (12%) of 
visits (intervention: 34/178, 19%; control: 10/186, 5%). At 12 months, unblinding was 
recorded for 35 (10%) of visits (intervention: 31/168, 18%; control: 4/174, 2%).  
The 703 anonymous participant session feedback forms showed 87.2% of respondents 
indicated the session met their needs (appendix 4.8a). Forms were received from all 10 sites 
with the number ranging 26 to 116 (appendix 4.8b). Mean weight change did not correlate 
with mean centre feedback scores, at 3 or 12 months (Spearmans rho = -0.20, p = 0.476 and 
Spearmans rho = 0.042, p = 0.454 respectively).  
Adverse events were similar between groups, except three deaths occurred in the 
intervention group; none were considered a result of the intervention (appendix 4.9).  
Cost-effectiveness analysis 
The two groups had similar EQ-5D-5L scores (Health Economics appendix). The intervention 
produced 0.0035 more QALYs. The mean total health and social care costs were £5,255 for 
STEPWISE participants and £4,453 for control participants. The mean total societal costs were 
£11,332 in STEPWISE participants and £10,305 in control participants. The incremental cost-
effectiveness ratio from the healthcare perspective is £246,921 and £367,543 from the 
societal perspective.  
Process evaluation 
Facilitator and participant courses were popular, and materials were adequately resourced, 
although doubts were expressed about financial sustainability. Professionals were generally 
motivated but expressed the concern that in some trusts human resource and leadership 
support were inadequate.  
Fidelity assessment of intervention delivery showed overall mean ± SD percentage facilitator 
talk time was 47.6 ± 12.3% (appendix 4.10). “Positive” (more facilitative) behaviours were 
observed for 54.1 ± 15.0% of the time. Conversely, “negative” (more didactic) behaviours 
were observed for 23.8 ± 15.4% of the time. Problems with fidelity included facilitators giving 
insufficient time for answering questions or completing tasks as well as providing rather than 
eliciting solutions from participants. Whilst the session structure provided dedicated space 
for participants to share their behavioural change successes and challenges, the intervention 
incorporated no objective assessment of whether participants had understood and were 
acting on programme content. There was difficulty delivering telephone support contacts, 
commonly because participants did not answer.  
 
Discussion 
The STEPWISE trial successfully recruited and retained participants; however, the 
intervention was neither clinically nor cost-effective over the 12-month intervention period. 
Both groups lost ~0.5 Kg but weight change did not differ between groups. There was no 
sustained behaviour change in diet and physical activity needed to promote weight loss. 
These results were unexpected as previous studies had indicated that non-pharmacological 
interventions could support weight reduction (3); however, most studies had fewer than 100 
participants, were of short duration, at moderate risk of bias and demonstrated substantial 
heterogeneity of effect size (11). NICE concluded that lifestyle interventions could reduce 
body weight in the short-term but effects beyond six months were unknown (11).  
Given our findings, we examined why the intervention did not work and the implications for 
future research and clinical practice. In terms of trial conduct, recruitment exceeded our 
target while satisfactory retention and data completeness for the primary outcome ensured 
the trial was adequately powered. The 1-year follow-up allowed a long-term perspective 
while assessor blinding reduced the risk of bias.  
STEPWISE was robustly developed in collaboration with people with schizophrenia and met 
UK Department of Health guidelines for structured education (18). The intervention was 
pragmatic, theory-based, feasible and appeared acceptable to both people with 
schizophrenia and mental healthcare professionals (19). Direct observation of sessions, the 
gold standard method for investigating fidelity, demonstrated that, despite the higher than 
expected turnover of facilitators, the intervention was delivered as planned and tailored 
appropriately.  
Although our findings are at odds with the effects of short term interventions, other long-
term studies have failed to demonstrate a benefit of lifestyle intervention. A recent meta-
analysis found significant weight loss in only two of six studies with interventions lasting 
longer than a year (7). The Danish CHANGE study, which randomised 428 people with 
schizophrenia spectrum disorders and abdominal obesity to 12 months of intensive lifestyle 
coaching plus care coordination plus usual care, or care coordination and usual care, or usual 
care alone, found no effect on body weight or waist circumference with either intervention 
(6). Two other recent UK lifestyle intervention trials have also not met their primary outcome 
(20, 21). 
It is instructive to compare the results of STEPWISE and CHANGE with two large US trials 
where weight loss was achieved.  In the ACHIEVE study, the intervention group lost on average 
3.2kg over 18 months (4) while in STRIDE, intervention participants lost 4.4 Kg more than 
control participants from baseline to 6 months but this difference reduced to 2.6 Kg at 1 year 
(5). Both ACHIEVE and STRIDE interventions were considerably more intensive than 
STEPWISE. ACHIEVE combined group weight-management sessions (weekly in the first 6 
months then monthly), monthly individual visits and thrice weekly group activity classes, 
while STRIDE study involved a 6-monthly weekly group intervention followed by six monthly 
maintenance sessions.  
The maximum face-to-face contact time in STEPWISE (17.5 hours) is similar to that 
recommended by the NHS Diabetes Prevention Programme and it is debatable whether a 
more intensive intervention would be feasible within many healthcare settings. Even 
accounting for the lower cost of delivering STEPWISE in real world clinical practice, a more 
intensive programme would likely be unaffordable, a concern raised by several facilitators. In 
STEPWISE, despite the successful pilot study and use of motivational techniques to engage 
participants, intervention uptake was challenging, as judged by the number of sessions 
attended, although the level of engagement was similar to other group based education 
programmes (22, 23).  
Intervention intensity, however, does not fully explain why STEPWISE was unsuccessful as the 
unsuccessful CHANGE included weekly 1-hour sessions for a year. Both STEPWISE and 
CHANGE recruited people with schizophrenia; by contrast, 41.9% of ACHIEVE participants and 
71% of STRIDE participants had mental illness other than schizophrenia spectrum disorders, 
for whom behaviour change may be easier to achieve. Whether STEPWISE would have been 
more successful for those with other psychotic illnesses, such as bipolar disorder, is unknown. 
By design, we included a broad representation of people with schizophrenia and first episode 
psychosis, although those with high levels of psychiatric symptoms were excluded. The 
participants had a spectrum of BMI from normal weight to morbid obesity. Most had a long 
history of established psychiatric disorder and around 40% were taking the second-line 
antipsychotic, clozapine. It is possible that the intervention could have been more effective 
during early psychosis, when weight gain is most rapid (2). Although we planned to include 
individuals shortly after the diagnosis of first episode psychosis, few participants had received 
treatment for less than 3 months, partly because of delays inherent in recruiting to a group 
intervention. 
To achieve meaningful weight loss, sustained behaviour change is needed. At baseline, 
participants ate an unhealthy diet and were physically inactive. Despite an opportunity to 
make a change, the intervention had little impact. One limitation of the intervention was the 
lack of objective feedback about participants’ progress to facilitators. The process evaluation 
indicated that facilitators wanted more information about participant weight change and 
nutritional and exercise plans to check understanding of session content and monitor dietary 
or physical activity changes against action plans. 
Notwithstanding the negative results, the trial has important findings. Despite concerns about 
undertaking trials in this population, we successfully delivered the largest trial in this area 
with a 12-month follow-up across a diverse group of community mental health teams. We 
achieved our recruitment target three months ahead of schedule and maintained participants 
throughout the year-long trial. The trial also highlighted patient and healthcare professional 
demand for weight-management programmes within mental health settings and, in response, 
several trusts increased their physical health monitoring and engagement with weight 
management. Participants also valued sharing experiences with other people with 
schizophrenia with similar weight problems.   
The challenge of managing obesity and weight gain in people with schizophrenia remains and 
other approaches are needed. STEPWISE focussed on lifestyle modification rather than the 
breadth of contributors to weight gain and obesity. Antipsychotics are associated with weight 
gain while psychosis and psychological factors can impede weight loss behaviours. Broader 
approaches that combine individually tailored lifestyle modification with psychological 
interventions for mental health, adjustment of antipsychotic treatment or co-prescription 
with drugs, such as metformin, may be needed (24).  
While it is clear that lifestyle change is needed for people with schizophrenia, STEPWISE has 
shown how difficult this is to achieve. NICE guidance currently recommends “people with 
psychosis or schizophrenia, especially those taking antipsychotics, should be offered a 
combined healthy eating and physical activity programme by their mental healthcare provider  
(11).” Before these lifestyle interventions are commissioned across the NHS, it is vital that 
further research is undertaken to address how best to support weight management.   
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Table 1. Baseline characteristics. Data are number (%) or mean (SD). Daily doses are median (IQR) in mg. Where 
long acting injectable medications have been used, the total dose has been divided by the dosing interval. 
Participants may have been taking more than one antipsychotic 
 
  Intervention (N=207)   Control (N=205)  
Age 40.0 (11.3) 40.1 (11.5)    
Male 115 (55.6%) 95 (46.3%) 
Female 92 (44.4%) 110 (53.7%) 
   
Schizophrenia diagnosis type   
ICD-10: F20 145 (70.0%) 138 (67.3%) 
ICD-10: F25 30 (14.5%) 36 (17.6%) 
First episode psychosis 32 (15.5%) 31 (15.1%) 
   
Time since starting antipsychotic 
medication (years)   
<1 year 12 (5.8%) 12 (5.9%) 
1-2 years 11 (5.3%) 20 (9.8%) 
2-5 years 28 (13.5%) 19 (9.3%) 
5-10 years 28 (13.5%) 33 (16.1%) 
10-20 years 71 (34.3%) 69 (33.7%) 
20 or more years 57 (27.5%) 52 (25.4%) 
   
Antipsychotic medication   Daily dose  Daily dose 
Haloperidol (oral) 7 (3.4%) 5 (5, 10) 3 (1.5%) 5 (1, 9) 
Amisulpride (oral) 21 (10.1%) 400 (400, 800) 16 (7.8%) 175 (100, 375) 
Aripiprazole (oral) 37 (17.9%) 10 (10, 15) 28 (13.7%) 10 (5, 15) 
Aripiprazole (long acting injection) 3 (1.4%) 14.3 (14.3, 14.3) 6 (2.9%) 14.3 (14.3, 14.3) 
Clozapine (oral) 89 (43.0%) 300 (250, 450) 81 (39.5%) 350 (250, 475) 
Olanzapine (oral) 31 (15.0%) 10 (5, 15) 31 (15.1%) 15 (10, 20) 
Quetiapine (oral) 28 (13.5%) 350 (175, 600) 24 (11.7%) 250 (100, 425) 
Risperidone (oral) 6 (2.9%) 4 (4,7) 16 (7.8%) 4 (4, 8) 
Risperidone (long acting injection) 4 (1.9%) 3.1 (2.7, 3.6) 5 (2.4%) 2.7 (1.8, 3.6) 
Flupentixol (injection) 8 (3.9%) 3.6 (3.2, 5.0) 11 (5.4%) 7.1 (2.9, 14.3) 
Zuclopenthixol (oral) 2 (1.0%) 19 (10, 28) 6 (2.9%) 7 (6, 20) 
Zuclopenthixol (long acting injection) 8 (3.9%) 23.2 (11.9, 32.1) 15 (7.3%) 14.3 (12.1, 35.7) 
Paliperidone (long acting injection) 7 (3.4%) 5.4 (2.7, 5.4) 8 (3.9%) 3.6 (2.2, 4.9) 
Other antipsychotic 19 (9.2%)  9 (4.4%)  
   
Ethnicity   
White European 179 (86.5%) 170 (82.9%) 
Asian 9 (4.3%) 7 (3.4%) 
Black 12 (5.8%) 19 (9.3%) 
Mixed 4 (1.9%) 7 (3.4%) 
Other 3 (1.4%) 2 (1.0%) 
   
Smoking status   
Ex-smoker 55 (26.6%) 52 (25.4%) 
Never smoked 54 (26.1%) 45 (22.0%) 
Current smoker 98 (47.3%) 108 (52.7%) 
   
Abnormal renal function 60 (29.0%) 58 (28.3%) 
Hepatic disease 5 (2.4%) 7 (3.4%) 
Diabetes 35 (16.9%) 25 (12.2%) 
Hypertension 21 (10.1%) 17 (8.3%) 
Cardiovascular disease 7 (3.4%) 12 (5.9%) 
 
Table 2. Outcome measures at baseline, 3-month and 12-month follow-up visits Baseline characteristics. Data are number (%) or mean (SD) or odds ratio (95% confidence 
intervals. Statistical analysis is on the basis of intention to treat 
 Baseline 3-month 12-month 
 
Intervention 
(N=207) 
Control (N=205) 
Intervention 
(N=178) 
Control (N=180) 
Difference between 
Intervention and 
Control 
Intervention 
(N=167) 
Control (N=173) 
Difference 
between 
Intervention and 
Control 
   Physical measures         
Weight (Kg) 105.2 (22.2) 102.1 (22.1) 104.7 (21.5) 103.1 (23.5) -0.55 (-1.44, 0.35) 104.1 (21.1) 101.3 (23.7) 0.04 (-1.58, 1.66) 
% weight change   -0.2 (4.4) 0.4 (4.7) -0.4% (-1.3%, 0.5%) -0.5 (7.9) -0.5 (8.3) 0.0% (-1.6%, 1.7%) 
Maintained or lost weight   93 (52.2%) 80 (44.2%) 1.35 (0.88, 2.05) 98 (58.3%) 88 (50.9%) 1.35 (0.85, 2.14)  
BMI (Kg/m2) 36.1 (7.2) 35.3 (7.2) 35.8 (7.1) 35.5 (7.4) -0.16 (-0.48, 0.15) 35.6 (7.2) 34.8 (7.3) 0.05 (-0.51, 0.61) 
Waist circumference (cm) 117.8 (15.6) 116.1 (17.4) 116.8 (15.2) 115.4 (17.0) 0.79 (-0.64, 2.22) 116.4 (16.1) 114.0 (17.7) 1.22 (-0.74, 3.20) 
Blood pressure 126 ± 16/82 ± 11 124 ± 17/82 ± 12 127 ± 16 / 82 ±11 123 ±16  / 81 ±12 
2.4 (0.2, 4.7) / 
0.4 (-1.5, 2.4) 
125  ± 15 / 82 ±10 122  ±16 /81 ±11 
1.7 (-1.1, 4.5)                    
1.1 (-0.7, 3.0) 
         
Biochemical measures         
HbA1c (mmol/mol) 42 (13) 40 (11)    43 (15) 41 (14) 0.2 (-1.4, 1.9) 
Fasting Glucose (mmol/L) 5.9 (2.2) 5.8 (2.3)    6.4 (3.0) 6.0 (2.8) 0.2 (-0.2, 0.7) 
Total cholesterol (mmol/L) 5.0 (1.2) 5.1 (1.2)    4.9 (1.2) 5.1 (1.1) -0.2 (-0.4, 0.1) 
HDL cholesterol (mmol/L) 1.2 (0.5) 1.2 (0.4)    1.2 (0.6) 1.2 (0.3) 0.0 (-0.1, 0.1) 
Triglycerides (mmol/L) 2.5 (2.0) 2.2 (1.7)    2.4 (1.4) 2.4 (2.2) -0.2 (-0.6, 0.1) 
         
Psychosocial measures         
RAND (general health) 45.0 (20.3) 44.8 (20.7) 48.0 (21.8) 46.8 (20.3) -0.3 (-3.4,2.8) 49.8 (23.1) 46.8 (21.4) 2.2 (-1.3,5.6) 
EQ5D 0.793 (0.201) 0.783 (0.187) 0.815 (0.165) 0.785 (0.214) 0.02 (-0.02, 0.054) 0.793 (0.237) 0.793 (0.239) -0.02 (-0.06, 0.03) 
B-IPQ 5.5 (1.5) 5.5 (1.7) 5.0 (1.7) 5.3 (1.7)  5.0 (1.9) 5.0 (1.7)  
BPRS 30.9 (8.8) 31.5 (9.4) 30.3 (9.0) 30.4 (9.4)  29.1 (9.7) 28.3 (9.5)  
PHQ9  10.6 (6.3) 11.0 (6.8) 10.3 (6.3) 10.1 (7.1)  9.9 (7.0) 9.6 (6.6)  
         
    Physical Activity         
MVPA* (All days) 13.3 (16.8) 11.0 (13.1) 13.3 (20.4) 8.8 (12.6)  2.0 (-0.9,  4.9) 15.4 (21.7) 11.8 (19.3)  1.5 (-2.5,  5.5) 
MVPA* (weekends) 9.6 (16.6) 9.6 (14.8) 11.3 (24.9) 7.4 (12.4) 5.6 ( 2.0,  9.3) 11.9 (22.1) 9.5 (19.2) 2.2 (-1.8,  6.2) 
MVPA* (weekdays) 14.4 (18.5) 11.6 (14.8) 13.8 (20.3) 9.5 (14.3)  0.9 (-2.0,  3.8) 16.6 (24.5) 12.6 (20.1)  1.0 (-3.9,  6.0) 
Mean Acceleration (All days) 21.3 (7.9) 20.8 (7.4) 21.7 (9.0) 19.8 (7.1) -0.4 (-1.5,  0.8) 22.4 (8.2) 20.5 (8.5)  0.2 (-1.4,  1.7) 
Mean Acceleration (Weekends) 19.6 (8.0) 19.8 (8.3) 20.4 (9.6) 18.7 (6.9)  1.0 (-0.3,  2.4) 20.9 (8.6) 19.4 (8.8)  0.3 (-1.5,  2.1) 
Mean Acceleration (Weekdays) 22.1 (8.3) 21.1 (7.1) 22.1 (9.2) 20.2 (7.5) -0.7 (-2.0,  0.6) 23.0 (8.5) 20.9 (8.6)  0.0 (-1.6,  1.6) 
: Odds ratios with 95% confidence intervals.  10 participants had BMI below 25 Kg/m2 at baseline (ranging from 19.5-24.9 Kg/m2); none of these was from a South Asian or Chinese background.  *MVPA (moderate-to-vigour physical activity) is assessed in bouts >10 minutes in 
duration. Baseline accelerometry data were obtained from 85% of participants of whom 76% provided valid data (≥4/7 days). Comparative data were available for 54% and 52% of participants at 3 and 12 months.  B-IPQ:  Brief Illness Perception Questionnaire ; BPRS:  Brief Psychiatric 
Rating Scale  ; PHQ9: 9-item Patient Health Questionnaire. 
Figure 1: Figure 1. The STEPWISE intervention 
Figure 1a. Theoretical Framework. The STEPWISE intervention was co-designed by a team 
with expertise in the development of obesity and lifestyle intervention programmes, mental 
healthcare professionals and researchers, and service users and refined during a four cycle 
pilot. It was underpinned by self-regulation and self-efficacy theories and the relapse 
prevention model. Figure 1b. Curriculum. The STEPWISE intervention comprised four 2.5 hour 
foundation group education sessions, designed to be delivered to small groups of 6-8 
participants over four consecutive weekly followed by three 2.5 hour follow-up ‘booster’ 
sessions at 3-monthly intervals and  fortnightly support, usually by telephone. The content 
was determined by the specific difficulties described by people with schizophrenia. The 
sessions incorporated adequate breaks. The educational style was non-judgmental and 
facilitative to allow the participants to discuss their beliefs about weight and explore own 
solutions. Strategies was employed to maintain engagement including telephone call 
reminders, provision of taxis to the venue, afternoon sessions with lunch provided, and use 
of incentives described as supporting tools. 
Figure 2: STEPWISE trial CONSORT diagram 
